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Abstract
Background: Recent warnings from Health
Canada regarding codeine for children have
led to increased use of nonsteroidal antiinflammatory drugs and morphine for common injuries such as fractures. Our objective
was to determine whether morphine administered orally has superior efficacy to ibuprofen
in fracture-related pain.
Methods: We used a parallel group, randomized, blinded superiority design. Children who
presented to the emergency department with
an uncomplicated extremity fracture were randomly assigned to receive either morphine
(0.5 mg/kg orally) or ibuprofen (10 mg/kg) for
24 hours after discharge. Our primary outcome
was the change in pain score using the Faces
Pain Scale — Revised (FPS-R). Participants were
asked to record pain scores immediately before
and 30 minutes after receiving each dose.
Results: We analyzed data from 66 participants in the morphine group and 68 participants in the ibuprofen group. For both morphine and ibuprofen, we found a reduction in
pain scores (mean pre–post difference ± stan-

T

here is ample evidence that analgesia is
underused,1 underprescribed,2 delayed in
its administration 2 and suboptimally
3
dosed in clinical settings. Children are particularly susceptible to suboptimal pain management4 and are less likely to receive opioid analgesia.5 Untreated pain in childhood has been
reported to lead to short-term problems such as
slower healing6 and to long-term issues such as
anxiety, needle phobia,7 hyperesthesia8 and fear
of medical care.9 The American Academy of
Pediatrics has reaffirmed its advocacy for the
appropriate use of analgesia for children with
acute pain.10
Fractures constitute between 10% and 25%
of all injuries.11 The most severe pain after an
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dard deviation for dose 1: morphine 1.5 ± 1.2,
ibuprofen 1.3 ± 1.0, between-group difference [δ] 0.2 [95% confidence interval (CI) –0.2
to 0.6]; dose 2: morphine 1.3 ± 1.3, ibuprofen
1.3 ± 0.9, δ 0 [95% CI –0.4 to 0.4]; dose 3: morphine 1.3 ± 1.4, ibuprofen 1.4 ± 1.1, δ –0.1
[95% CI –0.7 to 0.4]; and dose 4: morphine 1.5
± 1.4, ibuprofen 1.1 ± 1.2, δ 0.4 [95% CI –0.2
to 1.1]). We found no significant differences
in the change in pain scores between morphine and ibuprofen between groups at any
of the 4 time points (p = 0.6). Participants in
the morphine group had significantly more
adverse effects than those in the ibuprofen
group (56.1% v. 30.9%, p < 0.01).
Interpretation: We found no significant difference in analgesic efficacy between orally
administered morphine and ibuprofen. However, morphine was associated with a significantly greater number of adverse effects. Our
results suggest that ibuprofen remains safe
and effective for outpatient pain management in children with uncomplicated fractures. Trial registration: ClinicalTrials.gov, no.
NCT01690780.

injury occurs within the first 48 hours, with
more than 80% of children showing compromise in at least 1 functional area.12 Low rates of
analgesia have been reported after discharge
from hospital.13 A recently improved understanding of the pharmacogenomics of codeine
has raised significant concerns about its safety,14,15
and has led to a Food and Drug Administration
boxed warning16 and a Health Canada advisory17
against its use. Although ibuprofen has been cited
as the most common agent used by caregivers to
treat musculoskeletal pain,12,13 there are concerns
that its use as monotherapy may lead to inadequate pain management.6,18 Evidence suggests
that orally administered morphine13 and other opioids are increasingly being prescribed.19 However,
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Research
evidence for the oral administration of morphine
in acute pain management is limited.20,21 Thus,
additional studies are needed to address this gap
in knowledge and provide a scientific basis for
outpatient analgesic choices in children. Our
objective was to assess if orally administered
morphine is superior to ibuprofen in relieving
pain in children with nonoperative fractures.

Methods
Design and setting
We conducted a parallel-group, randomized,
blinded superiority trial designed to test the
hypothesis that orally administered morphine is
superior to ibuprofen for outpatient analgesia in
children with extremity fractures. We recruited
participants from September 2012 to February
2014 from the pediatric emergency department
of the Children’s Hospital, London Health Sciences Centre, in London, Ontario. This emergency department treats about 40 000 children
each year, 1900 of whom present with fractures.
We received approval for the trial from the
Office of Research Ethics on behalf of Western
University’s Research Ethics Board.
Participants
We included all children aged 5–17 years who
presented to the pediatric emergency department
with a nonoperative, radiographically evident
extremity fracture sustained within the preceding
24 hours. Our exclusion criteria were known
hypersensitivity to either ibuprofen or morphine,
chronic use of nonsteroidal anti-inflammatory
drugs (NSAIDS) or opioids, associated injuries
requiring analgesia, known renal disease, bleeding disorders, poor fluency in English, sleep
apnea and pregnancy. The participants consisted
of a convenience sample screened consecutively
for eligibility for 20 hours/week, between the
hours of 1200 and 2300. Written, informed consent and assent were obtained from all patients
or their legal g uardians.
A trained research assistant assessed eligibility, took participants’ informed consent or
assent, and performed all other correspondence
with participants. The research assistant was
invited to assess eligibility after the attending
physician’s interpretation of the radiograph.
Interventions
Randomization and concealment of allocation
were pharmacy-controlled by use of a computerbased random number generator (www‑users.
york.ac.uk/~mb55/soft/soft.htm). Eligible participants were randomly assigned in a 1:1 allocation
ratio with a stratified block design using a block

size of 6 to receive either normal-release morphine (ratio-MORPHINE; Ratiopharm, 0.5 mg/
kg, max. 10 mg) or ibuprofen (Advil; Pfizer Canada, 10 mg/kg, max. 600 mg) every 6 hours as
needed for pain for 24 hours after discharge
(max. 4 doses). Concealment of allocation was
performed by use of sequentially numbered,
opaque sealed envelopes. The interventions were
kept in identically appearing, nontranslucent
sealed containers. They were prepared by our
hospital pharmacy as opaque oral suspensions,
identical in appearance, and presented to participants in identical white plastic vials by a research
assistant. However, because the interventions differed in taste and consistency, we employed a
double-dummy setup whereby each participant
was given 4 prepackaged doses consisting of
2 vials, only 1 of which was the active agent. A
protocol for unmasking was available on an
emergency basis. Participants were counselled to
take acetaminophen at a dose of 15 mg/kg (max.
975 mg) for breakthrough pain.
Participants were given a data collection form
immediately before their discharge from the
emergency department, on which they were
asked to record pain using the Faces Pain
Scale — Revised (FPS-R) immediately before
and 30 minutes after each dose. The FPS-R is a
6-item self-report measure to assess the intensity
of pain. It has been validated with sound psychometric properties24 for use in children at least
4 years of age.25 The scale is scored from 0 (no
pain) to 5 (maximum amount of pain) by circling
the appropriate face on a horizontal axis.
Participants were also asked to record any
adverse effects that occurred within 72 hours of
the first dose and the number of acetaminophen
doses taken for breakthrough pain. We chose
30 minutes because the peak plasma concentration of morphine taken orally is reached at
30 minutes,22 and the peak plasma concentration
for ibuprofen is reached between 30 and 60 minutes.23 Participants returned the data forms using a
stamped, self-addressed envelope. All participants
received a phone call 24 hours after discharge to
remind them to return the forms, to enquire about
serious complications and to verify compliance.
We contacted participants who returned forms
with unclear information for clarification. Participants, investigators, the biostatistician and all
research assistants were blinded to allocation.
Outcome measures
Our primary outcome was the difference in pain
scale scores before and after the first dose of analgesic. Our secondary outcomes included the type
and frequency of adverse effects and the number
of participants who required a cetaminophen.
CMAJ, December 9, 2014, 186(18)
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Statistical analysis
A between-group difference in pain intensity
scores of 1 face has been shown to be a minimal
clinically important difference.24 Assuming a
standard deviation of 2 faces, 26 we needed
63 participants in each group to be able to detect
a 1-face between-group difference at 80% power
with a 2-sided level of significance of 0.05.
Our analysis was based on a modified
intention-to-treat principle and included all parti
cipants who took at least 1 dose of the intervention. We used means and standard deviations
(SDs), medians and interquartile ranges (IQRs)
or frequencies and percentages, as appropriate,
to summarize baseline characteristics. We
assessed comparisons between participants who
did and did not take analgesia using an unpaired
t test for continuous variables and a Pearson χ2
test for categorical variables. We used an
unpaired t test to assess the primary end point.
Similarly, for the second, third and fourth doses,
we used unpaired t tests to compare the 2 groups.
We used a mixed linear regression model with
Table 1: Characteristics of participants and their fractures, by study drug

Characteristic

Morphine
n = 66

Ibuprofen
n = 68

Age, yr, mean ± SD

10.7 ± 3.3

10.8 ± 3.1

Female sex, no. (%)

49 (74.2)

43 (63.2)

2 (1–3)

2 (1–3)

32 (48.5)

26 (38.2)

63

66

3

2

30

26

Discharge pain score,
median (IQR)
Closed reduction, no. (%)
Type of fracture, no.
Transverse
Torus
Location of fracture
Radius
Ulna

1

2

13

20

Clavicle

8

7

Humerus

5

5

Elbow

1

1

Forearm

2

0

Tibia or fibula

6

7

48

48

Splint

5

12

Sling

9

5

Collar and cuff

2

1

None

2

2

Radius + ulna

Type of immobilization
Circular cast

Note: IQR = interquartile range, SD = standard deviation.
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an unstructured covariance matrix to assess the
between-group differences across all 4 doses.
We used analysis of variance and a test of interaction to perform a prespecified subgroup analysis involving only those patients who underwent
closed reduction. We used a Pearson χ2 to evaluate between-group differences in the proportions
of participants who required breakthrough analgesia and had adverse effects.
We used the SPSS statistical software package
(version 19) for data analysis. We considered
p values less than 0.05 to be significant.

Results
Participants
Of the 183 participants who underwent randomization, 134 (73.2%) took at least 1 dose of the
intervention and were included in our analysis (66
participants from the morphine group and 68 from
the ibuprofen group) (Table 1, Figure 1). All of
the participants who did not take any of the study
drugs reported that they did not feel pain severe
enough to require an analgesic. There were no
significant differences between participants who
did take analgesia and those who did not with
respect to age (10.7 ± 3.2 v. 11.5 ± 3.2, p = 0.09),
sex (42 girls [31%] v. 18 girls [37%], p = 0.8),
median pain score on discharge (3 [IQR 2–4] v. 3
[IQR 2–4], p < 1.0) or number of closed reductions (56 [42%] v. 20 [41%], p = 0.45).
Primary outcome
Both morphine and ibuprofen resulted in a decrease
in pain scores at each dose administration. The
between-group difference in pre–post changes in
pain scores was not significant (Table 2).
Secondary outcomes
Between-group differences for the second, third
and fourth doses were not significant (Table 2).
We found no evidence that the differences in
pain scores changed over time (p = 0.3). For
each of the 4 doses, tests for heterogeneity were
nonsignificant whether or not the participant
had a closed reduction (p = 0.4, 0.4, 0.6 and
0.4, respectively).
There were no significant differences in the
percentage of participants requiring acetaminophen for breakthrough pain in the morphine or
ibuprofen groups (17 [25.7%] v. 10 [14.7%], p =
0.1). No severe adverse drug reactions (e.g.,
immune-mediated hypersensitivity) were reported
by any of the participants, and there were no
deaths. Significantly more participants in the morphine group had adverse effects, the most common of which was drowsiness (more than 1/3 of
participants in the morphine group, Table 3).

Research
Interpretation
In this randomized controlled study involving
children with nonoperative fractures, we show
that both morphine taken orally and ibuprofen
resulted in improved pain scores with no significant difference in analgesic efficacy. However,
morphine was associated with a greater frequency of adverse effects.
Concerns surrounding the safety of codeine in
children16,17 has left a void in the choices of opioid therapy available for moderate to severe
pain. As a possible consequence, some evidence
suggests that the use of oral morphine is increasing.13 However, our results suggest that ibuprofen remains a relatively safe and effective analgesic agent for children who have sustained a
nonoperative extremity fracture.
Two studies have investigated the use of
morphine to relieve pain in pediatric fractures.
In a single-arm trial, 0.5 mg/kg morphine
administered orally decreased pain scores at
30 minutes.20 In an observational study comparing morphine administered intravenously with
morphine administered orally, intravenous
administration (0.2–0.4 mg/kg) resulted in
greater pain reduction as assessed by a 5-item
faces pain scale.27 We found children in the
morphine group had significantly more adverse
effects. Previous studies have described similar
frequencies of nausea, vomiting and drowsiness,28 consistent with the expected adverse
effects of morphine.29
Our finding of a lack of analgesic superiority
of morphine over ibuprofen is consistent with
several studies involving children with orthopedic injuries. Ibuprofen has been found to be
more efficacious than either acetaminophen or
codeine, 18 equivalent to an acetaminophen–
codeine combination32 and equivalent to oxycodone.33 In the only study of outpatient analgesia
involving children with fractures, ibuprofen was

Not eligible n = 48

Patients
assessed for
eligibility
n = 340

•
•
•
•
•
•
•
•
•

Eligible
participants
n = 292

Currently involved in a
pain study n = 2
MD refused enrollment
n=3
Fracture > 24 hr n = 22
Admitted to hospital n
= 10
Insufficient study drugs
n=2
Chronic pain n = 1
Drug interaction n = 2
Poor English fluency n
=2
Hypersensitivity n = 4

Not enrolled n = 109
•

R
n = 183
•

Refused consent n = 103
- No reason given n = 78
- Prior dyspepsia with oral
morphine n = 1
- Uncomfortable with
randomization n = 2
- Preference for ibuprofen
n=1
- Not interested in study n = 3
- Parent or guardian unwilling
to give medication n = 5
- Family out of town n = 1
- History of medication refusal
n=3
- Parent/guardian/child feel
medication unnecessary
n=9
Discharged by MD n = 6

Ibuprofen
n = 94

Morphine
n = 89

Did not take study
drugs n = 23

Participants
included in
analysis
n = 66

Did not take study
drugs n = 26

Participants
included in
analysis
n = 68

Figure 1: Flow of participants through the trial. R = randomization.

Table 2: Mean pre–post differences in pain scores* between groups†
Oral morphine

Ibuprofen

No. of
participants

Pre–post difference,
mean ± SD

No. of
participants

Pre–post difference,
mean ± SD

Between-group difference
(95% CI)

p value‡

1

66

1.5 ± 1.2

68

1.3 ± 1.0

0.2 (–0.2 to 0.6)

0.3

2

55

1.3 ± 1.3

54

1.3 ± 0.9

0.0 (–0.4 to 0.4)

0.9

3

41

1.3 ± 1.4

48

1.4 ± 1.1

–0.1 (–0.7 to 0.4)

0.6

4

34

1.5 ± 1.4

36

1.1 ± 1.2

0.4 (–0.2 to 1.1)

0.2

Dose

Note: SD = standard deviation, CI = confidence interval.
*Determined using the Faces Pain Scale — Revised.
†Reflects the number of participants taking the dose of each medication at the corresponding time interval.
‡Unpaired t test.
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Table 3: Proportion of participants with adverse effects between groups
Patient group, no. (%)
Adverse effect*

Morphine
n = 66

Ibuprofen
n = 68

p value†

Any

37 (56.1)

21 (30.9)

< 0.01

Nausea

18 (27.3)

4

(5.9)

< 0.01

8 (12.1)

2

(2.9)

0.04

14 (20.6)

0.07

Vomiting
Drowsiness

23 (34.8)

Dizziness

8 (12.1)

6

(8.8)

0.5

Constipation

4

(6.1)

1

(1.5)

0.2

Other‡

8 (12.1)

3

(4.4)

0.1

*Some patients had more than 1 adverse effect.
†Pearson χ2 test.
‡Includes headache, abdominal pain, irritability and hyperactivity.

associated with less impairment in functional
outcomes and was more tolerable than acetaminophen plus codeine. Studies involving both
adults and children with a variety of painful conditions have shown that ibuprofen’s efficacy is
comparable with or superior to that of opioids.18,28,32,33 The possibility of comparable efficacy for musculoskeletal pain between NSAIDs
and opioids as drug classes is evidenced by other
studies that have shown ketorolac to be superior
to morphine 34 and equivalent to tramadol.35
Given ibuprofen’s and morphine’s similar and
inexpensive prices, in addition to these results
and ours, ibuprofen should be the initial drug of
choice for acutely painful musculoskeletal trauma
in children.
Limitations
To preserve blinding, participants took the intervention no more frequently than every 6 hours.
However, the duration of action of normalrelease morphine taken orally is 2 to 4 hours.22
Acetaminophen for breakthrough pain may have
decreased the preintervention pain scores in the
morphine group, providing a more conservative
estimate of effect size.
Our study design favoured the pragmatic end
of the Pragmatic–Explanatory Continuum Indicator Summary.36 Our intent was to determine the
effects of analgesia under typical outpatient conditions. However, broad inclusion criteria may
have added substantial between-subject variability, thereby decreasing power. We allowed participants to take analgesia on an as-needed basis
because analgesic requirements after fracture
immobilization are not universal, and fixed dosing may have led to noncompliance12 without
benefiting short-term functional outcomes. 12
Although as-needed dosing may have under1362
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mined randomization, there were no significant
differences in parameters that may have influenced the response to analgesia when we compared participants who did and did not take the
intervention.
The bioavailability of morphine is influenced
by renal30 and hepatic function.31 We did not
evaluate these parameters. However, because all
of the participants who underwent randomization
were children who were otherwise healthy, we
surmised that there would be little heterogeneity
in pharmacokinetic parameters that could affect
our primary outcome.
Finally, our study was a negative trial in that
we did not find significant superiority in efficacy of morphine over ibuprofen. We chose to
compare morphine against an active comparator
primarily because a participant randomly
assigned to a placebo may decide to take an
analgesic agent if they are in pain. We felt this
would contaminate the trial with a cointervention that may be inconsistent with respect to
agent, dose and frequency. Although our study
was powered to detect a minimal clinically
important difference of 1 face on the FPS-R, it
was not powered to detect between-group differences in adverse effects, analgesia for breakthrough pain or pain between reduced and nonreduced fractures.
Conclusion
Both morphine taken orally and ibuprofen
showed analgesic efficacy in children with fractures for the first 24 hours after their discharge
from the emergency department, and there were
no significant differences between the 2 agents.
Given that morphine was associated with significantly more adverse effects, we conclude that
ibuprofen remains a safe and effective therapy for
outpatient management of children’s fracture
pain. We hope that our results will provide clinicians with a foundation for rational analgesic
choices for children with fractures who are discharged from the emergency department. Possible future research includes evaluating the role of
single-dose morphine administered orally for
breakthrough pain in children, as well as combination therapy of ibuprofen with m
 orphine.
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